Biocon Limited has informed the Exchange regarding a press release dated August 03, 2026, titled "Biocon Announces U.S. Commercial Launch of Yesafili , a Biosimilar to Regeneron s Eylea® 2 mg".
Biocon Limited Press Release Aug 03 2026
Earlier from Biocon
- Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili, a Biosimilar to Eylea
- Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili™, a Biosimilar to Eylea® (Aflibercept)
- Biocon Limited Press Release Jul 09 2026
- Biocon Limited Press Release Jun 24 2026